Elemental impurities in pharmaceutical products can pose risks to patient safety and product quality. Even at trace levels, certain elemental impurities may present toxicological concerns, contribute to cumulative exposure, or potentially impact drug product stability. Monitoring and controlling these impurities are essential to maintaining pharmaceutical quality and meeting applicable regulatory requirements.
Understanding where these impurities originate is the first step toward developing an appropriate testing and control strategy. ICH Q3D(R2), USP <232> and USP <233> provide a risk-based framework for evaluating potential sources, setting exposure limits and selecting suitable analytical procedures.
What Are Elemental Impurities in Pharmaceutical Testing?
Elemental impurities are trace elements that may be present in pharmaceutical raw materials, active pharmaceutical ingredients (APIs), excipients, or finished drug products without providing therapeutic benefit. These impurities may originate from residual catalysts, manufacturing equipment, raw materials, packaging components, or other sources throughout the pharmaceutical manufacturing process.
Elemental impurities are classified as inorganic impurities and may pose toxicological risks depending on the specific element, concentration, route of administration, and duration of exposure.
Unlike traditional heavy metals testing, modern pharmaceutical elemental impurities testing focuses on identifying and quantifying individual elements using a risk-based approach. Regulatory guidelines, including ICH Q3D and USP <232> and <233>, establish principles for assessing and controlling elemental impurities based on permitted daily exposure (PDE) limits and appropriate analytical procedures.
Why Elemental Impurities Matter in Pharmaceuticals
Certain elemental impurities in pharmaceutical products, including arsenic, cadmium, mercury, and lead, can pose toxicological risks even at low exposure levels. Depending on the element and its chemical form, repeated or prolonged exposure may increase health risks, making elemental impurity control particularly important for medications used over extended periods.
Beyond patient safety, elemental impurities can also affect drug product quality and stability. Residual metal catalysts and other trace elements may interact with active pharmaceutical ingredients (APIs) or contribute to degradation reactions, potentially impacting product stability and consistency.
Pharmaceutical elemental impurities testing uses a risk-based approach guided by ICH Q3D and USP <232> and <233>. Unlike general trace metals screening, pharmaceutical testing considers element-specific toxicity, permitted daily exposure (PDE) limits, route of administration, and potential sources of contamination to support product quality and regulatory compliance.
Common Sources of Elemental Impurities in Pharmaceutical Products
Elemental impurities in pharmaceutical products can originate from several sources, including raw materials, active pharmaceutical ingredients (APIs), excipients, water, and manufacturing processes. Certain elements may be intentionally introduced as catalysts or reagents during drug synthesis and remain as residual impurities if not adequately removed.
Pharmaceutical manufacturing equipment can also introduce trace metals through corrosion, abrasion, or contact with stainless steel and other metal alloys. The potential for contamination depends on equipment materials, manufacturing conditions, and established process controls.
Additionally, container-closure systems, packaging materials, and drug-delivery devices may contribute elemental impurities through leaching during storage or use. These potential sources should be evaluated as part of a risk-based elemental impurities assessment and, when appropriate, considered alongside extractables and leachables (E&L) studies.
The ICH Q3D(R2) Regulatory Framework for Elemental Impurities
ICH Q3D(R2) provides an internationally recognized, risk-based framework for identifying, assessing, and controlling elemental impurities in pharmaceutical drug products. The guideline establishes permitted daily exposure (PDE) limits for elements of toxicological concern and helps manufacturers develop appropriate control strategies based on product composition, manufacturing processes, and route of administration.
Rather than requiring routine testing for every element, ICH Q3D(R2) emphasizes evaluating potential contamination sources and patient exposure. European Pharmacopoeia (Ph. Eur.) Chapter 5.20 also addresses elemental impurities in applicable medicinal products, incorporating principles from ICH Q3D.
ICH Q3D Elemental Impurity Classes
CH Q3D categorizes 24 elemental impurities into four groups based on toxicity and the likelihood of their presence in pharmaceutical products.
- Class 1 – Arsenic (As), Cadmium (Cd), Mercury (Hg), and Lead (Pb): Elements of significant toxicological concern that should be evaluated during elemental impurity risk assessments due to their potential presence in pharmaceutical materials.
- Class 2A – Cobalt (Co), Nickel (Ni), and Vanadium (V): Elements with a relatively high likelihood of occurrence that generally require evaluation across potential contamination sources.
- Class 2B – Silver (Ag), Gold (Au), Iridium (Ir), Osmium (Os), Palladium (Pd), Platinum (Pt), Rhodium (Rh), Ruthenium (Ru), Selenium (Se), and Thallium (Tl): Elements with a lower probability of occurrence that generally require evaluation when intentionally added during manufacturing.
Class 3 – Barium (Ba), Chromium (Cr), Copper (Cu), Lithium (Li), Molybdenum (Mo), Antimony (Sb), and Tin (Sn): Elements with relatively low oral toxicity that may require additional consideration for parenteral and inhalation products.The specific elements evaluated depend on the drug product’s composition, manufacturing process, potential contamination sources, and route of administration. ICH Q3D does not require every pharmaceutical product to be tested for all 24 elements.
Permitted Daily Exposures (PDE) and Administration Routes
A permitted daily exposure (PDE) represents the maximum acceptable daily exposure to an elemental impurity based on toxicological evaluation.
ICH Q3D establishes element-specific PDE limits that vary by route of administration, including oral, parenteral, and inhalation routes. ICH Q3D(R2) also includes guidance for cutaneous and transcutaneous products.
When determining acceptable elemental impurity concentrations, manufacturers must consider the applicable PDE and maximum daily dose of the drug product.
How an Elemental Impurity Risk Assessment Works
An elemental impurity risk assessment identifies potential sources of elemental contamination and evaluates whether patient exposure is adequately controlled.
Manufacturers may use raw material specifications, supplier information, manufacturing process knowledge, historical testing data, and analytical results to assess potential risks.
Two common approaches include evaluating elemental impurities contributed by individual drug product components or assessing representative finished-product batches. The appropriate strategy depends on product-specific risks and available supporting information.
The Three-Step Assessment and Control Process
- Identify Potential Sources: Evaluate elemental impurities that may originate from APIs, excipients, raw materials, catalysts, manufacturing equipment, and container-closure systems.
- Evaluate Potential Exposure: Estimate or measure elemental impurity concentrations and compare anticipated daily exposure with applicable PDE limits.
- Establish Appropriate Controls: Determine whether existing controls are sufficient or whether additional material specifications, process controls, or analytical testing are necessary.
ICH Q3D establishes a control threshold of 30% of the applicable PDE. When predicted or measured elemental impurity levels are consistently below this threshold and supported by an adequate risk assessment, additional controls may not be necessary.
USP <232> and <233> Elemental Impurity Testing
USP <232> specifies limits for elemental impurities in drug products. It requires assurance that applicable impurities remain within established levels when they are known to be present, intentionally added or reasonably capable of entering the product.
USP <233> addresses the analytical procedures used to determine elemental impurity concentrations. It describes compendial procedures based on inductively coupled plasma techniques and establishes performance expectations for demonstrating that a procedure is suitable for its intended use.
Together, the chapters connect exposure limits with reliable analytical measurements. Pharmaceutical companies that need support interpreting or applying these chapters can learn more about BA Sciences’ USP <232> and <233> elemental impurity testing.
How Are Elemental Impurities Tested?
Pharmaceutical elemental impurities testing involves identifying and quantifying trace elements using sensitive analytical techniques. The appropriate testing method depends on the target elements, sample matrix, expected concentrations, and applicable regulatory limits.
ICP-MS and ICP-OES
Inductively Coupled Plasma Mass Spectrometry (ICP-MS) is widely used for trace and ultra-trace elemental analysis. Its high sensitivity and multi-element detection capabilities make it particularly valuable for evaluating elemental impurities at low concentrations.
Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES) provides an alternative for multi-element analysis when its sensitivity and analytical performance meet the required specifications.
Atomic absorption spectroscopy may also be appropriate for certain elemental testing applications when the method is demonstrated to be suitable for its intended purpose.
Sample Preparation, Validation and Contamination Control
Accurate elemental impurity testing requires appropriate sample preparation, contamination controls, and analytical method validation or verification.
Depending on the material and target elements, sample preparation may include dilution, extraction, or acid digestion. Laboratories must also account for potential contamination from reagents, water, equipment, and sample handling.
Analytical method performance is evaluated against applicable requirements, including USP <233>, where relevant. Important performance characteristics may include accuracy, precision, specificity, quantitation limits, and range.
Appropriate calibration, spike-recovery studies, procedural blanks, and interference assessments help demonstrate reliable elemental impurity measurements.
Supporting Elemental Impurity Regulatory Documentation
A well-documented elemental impurity risk assessment provides evidence supporting the selection of target elements, evaluation of potential contamination sources, and comparison of anticipated exposure with applicable PDE limits.
Supporting documentation may include analytical procedures, method validation or verification records, testing results, material specifications, and established control strategies.
These records help pharmaceutical manufacturers demonstrate that elemental impurities are appropriately assessed and controlled throughout the drug product lifecycle.
Elemental Impurities Testing Services at BA Sciences
BA Sciences provides elemental impurities testing and trace metal analysis services for pharmaceutical and biopharmaceutical manufacturers. Our analytical capabilities include ICP-MS testing to identify and quantify elemental impurities in pharmaceutical raw materials, active pharmaceutical ingredients (APIs), excipients, and drug products.
As a cGMP-compliant analytical testing laboratory, BA Sciences supports analytical method development, validation, compendial testing, and pharmaceutical quality control. Our experienced scientists work closely with clients to develop testing strategies tailored to their product matrices, target elements, and applicable regulatory requirements.